论文部分内容阅读
目的:探讨以毒结清口服液治疗多发性骨髓瘤(MM)患者骨病的临床疗效。方法:将42例MM患者随机分成两组,对照组20例予M2方案化疗,中药组22例予中药毒结清口服液60mL/d,同时予M2方案化疗。以血钙和白介素-6(IL-6)水平下降,骨痛的缓解和生活质量改善为评价指标。结果:中药组和对照组治疗后骨痛症状评分均明显下降,与治疗前比较差异均有显著性意义(P<0.05);中药组生活质量总有效率为68.2%,与对照组总有效率(45%)比较差异均有显著性意义(P<0.05);中药组治疗后血钙和IL-6水平均明显下降(P<0.05),与对照组治疗后血钙和IL-6水平比较差异也有显著性意义(P<0.05);对照组治疗后血钙水平较治疗前有下降(P>0.05)。结论:毒结清口服液联合化疗能有效降低MM患者血钙和IL-6水平,改善骨痛症状,提高生活质量。
Objective: To investigate the clinical efficacy of Tongjiqing oral liquid in the treatment of bone disease in patients with multiple myeloma (MM). Methods: Forty-two patients with MM were randomly divided into two groups. Twenty patients in the control group received chemotherapy with M2 regimen. Twenty-two patients in the TCM group received 60 mL / d of Chinese drug group. To calcium and interleukin -6 (IL-6) levels decreased, ease of bone pain and quality of life as the evaluation index. Results: The score of pain symptom of the traditional Chinese medicine group and the control group were significantly decreased after treatment (P <0.05), the total effective rate of the quality of life of the traditional Chinese medicine group was 68.2%, which was significantly lower than that of the control group (45%) (P <0.05). The levels of serum calcium and IL-6 in Chinese medicine group were significantly lower than those in control group (P <0.05). Compared with the control group, the levels of serum calcium and IL-6 (P <0.05). The blood calcium level of the control group decreased after treatment (P> 0.05). Conclusion: Tongjiqing oral solution combined with chemotherapy can effectively reduce the levels of serum calcium and IL-6 in MM patients, improve the symptoms of bone pain and improve the quality of life.